SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron (MU) is trending following an "impressive" quarterly report that included results and guidance exceeding consensus estimates, with analysts subsequently raising price targets. The community is closely watching the stock's price action, debating whether the positive news was already priced in, while also considering the broader AI market and potential overbought conditions. Some traders are expressing frustration with perceived market manipulation and highlighting Micron's growth potential.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure is trending due to positive three-year data on its Huntington's disease drug, AMT-130, exceeding expectations and potentially derisking accelerated FDA approval. Community discussions revolve around the halted stock, potential gap up, and possible links to CLPT, with some expressing concerns about a sharp sell-off. There is also active discussion about potential FDA approval.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending due to its recent partnership with Red Lobster to implement AI-powered phone ordering across all locations, sparking excitement about potential future deals with larger chains like McDonald's. The community is also focused on the high short interest, anticipating a potential short squeeze, with some highlighting the broader implications of AI adoption across various industries. Bullish sentiment is fueled by the company's growth potential and innovative technology in the voice AI space.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending as investors digest a Wells Fargo upgrade citing expected AWS sales acceleration and a hardware event on September 30th, though some community members express frustration with the stock's YTD performance compared to its peers. Discussions also include the FTC trial regarding Prime enrollments and closures of Amazon Fresh stores in the UK. Some traders are anticipating a potential dip while others are loading up for a Q4 rally.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending as news circulates about the company's AI advancements and partnerships, including a collaboration with Nvidia on physical AI and plans to increase AI spending. The community is buzzing with bullish sentiment, viewing BABA as undervalued and drawing comparisons to other tech giants like Amazon and Nvidia. Some traders note China's push for AI self-sufficiency and believe the stock could see substantial growth despite geopolitical concerns.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

OPEN is seeing active discussion around a recent pullback after a significant run, with community members debating whether it's a buying opportunity or a sign of further decline. The conversation also highlights the influence of board member actions and prominent investors, with some suggesting their moves are impacting the stock's volatility. Community members are weighing the potential impact of upcoming housing data and the company's long-term prospects amid the recent price swings.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as investors discuss potential catalysts, including government investment and regulatory approvals, that could drive significant growth. The community is highlighting the company's progress in deep-sea mining and its potential role in securing critical mineral supplies. Bullish sentiment is building, with some anticipating multi-bagger returns upon full production.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

ZVRA is trending due to increased volume and community speculation about potential catalysts, including a possible buyout, upcoming presentations, and the Delaware court case. Community members are discussing insider buying, institutional ownership, and the potential impact of warrants expiring in January 2026. Some are expressing frustration with management and debating whether the stock is undervalued or a value trap.

Firecoin is a digital asset inspired by the concept of the eternal flame, representing energy, resilience, and guidance. It is designed to act as a decentralized token that embodies light and strength, giving holders a sense of empowerment in the digital economy. The project’s purpose is to create a community-driven ecosystem where Firecoin symbolizes progress, illumination, and the ability to move forward regardless of challenges. By leveraging blockchain technology, Firecoin aims to provide transparency, security, and accessibility to its users while maintaining its thematic connection to the symbolic power of fire.

firecoin

Enthusiasm for FIRECOIN.X is building, with many community members signaling they are buying in, anticipating a surge. The coin, associated with the Solana ecosystem, is being actively discussed in the context of potential 'moon flights' and 'fire gains'. Some users are also inquiring about which platforms the crypto can be purchased on.

Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform consists of the ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Solana Beach, CA.

ClearPoint Neuro Inc

ClearPoint Neuro ($CLPT) is trending as the community discusses its potential link to gene therapy companies like $QURE and recent FDA approvals in the neuro space, sparking interest in its role in delivering these therapies to the brain. Community members are also pointing to a recently published article and increased chatter from financial influencers as potential catalysts. Bullish sentiment is building due to strong technicals and the expectation of continued growth within the neuro indications sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

uniQure N.V. (QURE) on Wednesday said that a high dose of its experimental drug AMT-130 demonstrated a statistically significant slowing of disease progression in Huntington’s disease in an early-to-mid stage trial.Huntington’s disease is a rare, inherited neurodegenerative disorder that leads to motor symptoms including chorea, behavioral abnormalities, and cognitive decline. The company stated that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale (cUHDRS), a comprehensive assessment tool used in clinical trials for Huntington's disease.Shares of the company rose 3% in the pre-market session at the time of writing.&nbsp;Get updates to this developing story <a href="https://stocktwits.com/news-articles/markets/equity/uniqure-stock-rises-pre-market-after-investigational-huntingtons-disease-drug-slows-disease-in-trial/chD1GAOR33X">directly on Stocktwits.</a>

Global stock market chart and trading board - stock photo

uniQure Stock Rises Pre-Market After Investigational Huntington’s Disease Drug Slows Disease In Trial 

The company stated that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale. 

Equity

The company stated that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale. 


Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet

The consensus price target hints at a 142.7% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

uniQure (QURE) delivered earnings and revenue surprises of +22.47% and -26.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

3 Top Genomics Stocks to Add to Your Portfolio in 2025

Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?

Shares of uniQure N.V. (QURE) were in the spotlight on Friday morning after its first quarter (Q1) revenue fell 81% year-on-year (YoY) while losses narrowed.The gene therapy company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/05/09/3078125/0/en/uniQure-Announces-First-Quarter-2025-Financial-Results-and-Highlights-of-Recent-Company-Progress.html">reported</a> revenue for the three months ended March of $1.6 million, compared to $8.5 million in the same period of 2024, and below an analyst estimate of $6.71 million, as per Finchat data.The company attributed the revenue fall to a decrease of $4 million in contract manufacturing of HEMGENIX gene therapy for biotherapeutics company CSL Behring, among other factors.uniQure, however, narrowed its quarterly loss to $0.82 per share, compared to a loss of $1.36 in the corresponding period of 2024. Analysts were estimating a loss of $1.06 per share.The narrowing of the net loss in the quarter was driven by a significant reduction in the company’s operating expenses, as it slashed employee-related expenses, facility expenses, and costs related to preclinical supplies.The firm ended the quarter with cash, cash equivalents, and current investment securities of approximately $409 million, expected to fund its operations into the second half of 2027.The company is now seeking U.S. FDA approval for its AMT-130 gene therapy as a treatment for Huntington’s disease.CEO Matt Kapusta said that the company expects to provide a regulatory update on AMT-130 in the second quarter, including guidance on the potential timing for its application to the FDA seeking approval to distribute the therapy.On Stocktwits, retail sentiment around uniQure remained unmoved within the ‘neutral’ territory over the past 24 hours while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:630/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_09_at_8_08_00_AM_png_281dbf2952.webp" alt="QURE's Sentiment Meter and Message Volume as of 8:08 a.m. ET on May 9, 2025 | Source: Stocktwits" width="630" height="63"><figcaption>QURE's Sentiment Meter and Message Volume as of 8:08 a.m. ET on May 9, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/QURE/sentiment">QURE stock</a> declined by 32% this year but is up by about 142% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-reports-positive-data-from-cancer-drug-trial/chiWpd3RblJ">AstraZeneca Reports Positive Data From Cancer Drug Trial: Retail Sentiment Brightens</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

UniQure Narrows Q1 Loss But Revenue Plummets: Retail’s In Wait-And-Watch Mode

The company narrowed its first-quarter loss to $0.82 per share, down from $1.36 per share in 2024. 

Biotech stocks jump as Makary outlines FDA vision, RBC comments

Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In his first major interview since taking office, Makary emphasized pragmatic reforms, faster drug approvals, and modernized use of real-world data across the agency.

Shares of gene therapy developer uniQure N.V. (QURE) shot up 41% on Thursday afternoon after it <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.uniqure.com/investors-media/press-releases">announced</a> that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to its AMT-130 gene therapy for the treatment of Huntington’s disease.The new designation is in addition to the existing Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, and Fast Track designations granted to AMT-130.uniQure CEO Walid Abi-Saab said that the designation underscores both the urgent need for effective treatments for Huntington’s disease and the encouraging interim data demonstrating that AMT-130 has the potential to slow disease progression.He added that the company looks to commercialize the drug as quickly as possible.Forty-five patients have received AMT-130 to date as part of trials, the company stated, while adding that an additional regulatory update regarding its Biologics License Application submission to the FDA requesting marketing approval is expected in the second quarter.Huntington’s disease is a rare, inherited neurodegenerative disorder. According to a 2021 study in Neuroepidemiology, approximately 70,000 people have been diagnosed with Huntington’s disease in the U.S. and Europe, with hundreds of thousands of others at risk of inheriting it.FDA’s Breakthrough Therapy designation is intended to expedite the development and review of investigational therapeutic candidates that are intended to treat a serious condition, and if preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy.On Stocktwits, retail sentiment around uniQure flipped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours while message volume jumped from ‘low’ to ‘extremely high’.<figure class="image"><img style="aspect-ratio:1292/302;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_17_at_12_38_37_PM_png_86c013b014.webp" alt="QURE's Sentiment Meter and Message Volume as of 12:40 p.m. ET on April 17, 2025 | Source: Stocktwits" width="1292" height="302"><figcaption>QURE's Sentiment Meter and Message Volume as of 12:40 p.m. ET on April 17, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/QURE">QURE stock</a> is down approximately 27% year-to-date but up about 183% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/spirit-airlines-appoints-dave-davis-as-ceo/chQEDnoRbfA">Spirit Airlines Appoints Dave Davis As CEO After Emerging From Bankruptcy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic

The new designation is in addition to the existing Regenerative Medicine Advanced Therapy, Orphan Drug, and Fast Track designations granted to AMT-130.

CSL Behring's Gene Therapy HEMGENIX (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

CSL Behring's Gene Therapy HEMGENIX (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B CSL Behring's Gene...

Shares of gene therapy company uniQure more than doubled on Tuesday before trimming some gains, reaching their highest levels since mid-June 2023.The surge came after uniQure announced it had reached an agreement with the U.S. Food and Drug Administration (FDA) on key aspects of an Accelerated Approval pathway for its AMT-130 treatment, a potential therapy for Huntington’s disease.&nbsp;This agreement means data from the ongoing Phase I/II studies, compared to an external control, could serve as the primary basis for a biologics license application (BLA) submission without requiring an additional pre-submission study.uniQure’s AMT-130 previously received a regenerative medicine advanced therapy (RMAT) designation from the FDA in May, underscoring its potential to address unmet medical needs in Huntington’s disease.&nbsp;Analysts have viewed this development as a major milestone.Cantor Fitzgerald analyst Kristen Kluska raised her price target for uniQure to $58 from $28 and maintained an ‘Overweight’ rating, noting that the FDA’s approval signals potential pharma interest given the clearer path toward market entry.Stifel also weighed in, describing the development as “a best-case scenario” and noting that uniQure can use external controls and data from ongoing studies.&nbsp;Stifel has a ‘Buy’ rating and predicts the FDA agreement will bolster confidence in uniQure’s pipeline, despite the low initial expectations for this accelerated pathway.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/QURE_sentiment_and_message_volume_Dec_10_premarket_98c55fcc19.png" alt="QURE sentiment and message volume Dec 10 premarket.png" width="1318" height="324"><figcaption>QURE sentiment and message volume Dec 10 premarket as of 11:45 am ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned ‘extremely bullish’, with QURE trending among the top 10 tickers late Tuesday morning.<stembedurl>https://stocktwits.com/nbkihy8/message/595867060</stembedurl><stembedurl>https://stocktwits.com/DaBeavzz65/message/578931944</stembedurl>uniQure’s stock has more than doubled in value this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Neurons in dementia, conceptual illustration - stock illustration

uniQure Stock Hits 18-Month High After FDA Agreement Clears Pathway For Huntington’s Treatment: Retail Gets More Optimistic

uniQure’s AMT-130 previously received a regenerative medicine advanced therapy designation from the FDA in May.

https://files.quartr.com/streams/2025-09-24/56917cfe-6c9b-4765-ac40-11063cfa1b01/2/live_transcript.jsonl?ref=U3RvY2t0d2l0cw==

Study Result

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

QURE
uniQure N.V.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest QURE News

QURE uniQure N.V.